A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia

PLoS ONE

Volumn 13, Issue 1, 2018, Pages

  Varshney, Avanish K ^a,b   Kuzmicheva, Galina A ^a   Lin, Jian B ^a,c   Sunley, Kevin M ^a   Bowling, Rodney A ^a   Kwan, Tzu Yu ^a   Mays, Heather R ^a   Rambhadran, Anu ^a,d   Zhang, Yanfeng ^a   Martin, Rebecca L ^a   Cavalier, Michael C ^a   Simard, John ^a   Shivaswamy, Sushma ^a  

^a XBiotech USA Inc   (United States)

^b Luye Pharma USA   (United States)

^c WUXI APPTEC   (China)

^d REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 514G3; STAPHYLOCOCCUS PROTEIN A; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY ISOLATION; ANTIBODY TITER; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; OPSONOPHAGOCYTOSIS; PHAGOCYTOSIS; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR BINDING; STAPHYLOCOCCAL BACTEREMIA; PH;

HYDROGEN-ION CONCENTRATION;

EID: 85041108303     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0190537     Document Type: Article

References (61)

1. Frank DN, Feazel LM, Bessesen MT, Price CS, Janoff EN, Pace NR. The human nasal microbiota and Staphylococcus aureus carriage. PLoS One. 2010; 5(5):e10598. Epub 2010/05/26. https://doi.org/10.1371/journal.pone.0010598 PMID: 20498722.
2. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis. 1998; 26(5):1179–81. Epub 1998/05/23. PMID: 9597249.
3. DeLeo FR, Diep BA, Otto M. Host defense and pathogenesis in Staphylococcus aureus infections. Infect Dis Clin North Am. 2009; 23(1):17–34. Epub 2009/01/13. https://doi.org/10.1016/j.idc.2008.10. 003 PMID: 19135914.
4. Coates R M J, Horsburgh MJ. Staphylococci: colonizers and pathogens of human skin. Future Microbiol. 2014;Jan; 9:75–91. https://doi.org/10.2217/fmb.13.145 PMID: 24328382
5. Brown AF L J, Rogers TR, McLoughlin RM. Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design. Front Immunol. 2014;Jan 8; 4:507. https://doi.org/10.3389/fimmu.2013.00507 PMID: 24409186
6. Ziakas PD, Anagnostou T, Mylonakis E. The Prevalence and Significance of Methicillin-Resistant Staphylococcus aureus Colonization at Admission in the General ICU Setting: A Meta-Analysis of Published Studies*. Crit Care Med. 2014; 42(2):433–44. Epub 2013/10/23. https://doi.org/10.1097/CCM. 0b013e3182a66bb8 PMID: 24145849.
7. Stryjewski ME, Corey GR. Methicillin-Resistant Staphylococcus aureus: An Evolving Pathogen. Clin Infect Dis. 2014; 58 Suppl 1:S10–9. Epub 2013/12/18. https://doi.org/10.1093/cid/cit613 PMID: 24343827.
8. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis. 2005; 5(5):275–86. Epub 2005/04/28. https://doi.org/10.1016/S1473-3099(05)70112-2 PMID: 15854883.
9. Francois B, Barraud O, Jafri HS. Antibody-based therapy to combat Staphylococcus aureus infections. Clin Microbiol Infect. 2017. https://doi.org/10.1016/j.cmi.2017.02.035 PMID: 28274770.
10. Salgado-Pabon W, Schlievert PM. Models matter: the search for an effective Staphylococcus aureus vaccine. Nat Rev Microbiol. 2014; 12(8):585–91. https://doi.org/10.1038/nrmicro3308 PMID: 24998740.
11. Verkaik NJ, van Wamel WJ, van Belkum A. Immunotherapeutic approaches against Staphylococcus aureus. Immunotherapy. 2011; 3(9):1063–73. https://doi.org/10.2217/imt.11.84 PMID: 21913829.
12. Otto M. Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin Biol Ther. 2010; 10(7):1049–59. Epub 2010/06/10. https://doi.org/10.1517/14712598.2010.495115 PMID: 20528609.
13. Yang Y, Qian M, Yi S, Liu S, Li B, Yu R, et al. Monoclonal Antibody Targeting Staphylococcus aureus Surface Protein A (SasA) Protect Against Staphylococcus aureus Sepsis and Peritonitis in Mice. PLoS One. 2016; 11(2):e0149460. https://doi.org/10.1371/journal.pone.0149460 PMID: 26926145.
14. Aguilar JL, Varshney AK, Pechuan X, Dutta K, Nosanchuk JD, Fries BC. Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus. Virulence. 2016:1–10. https://doi.org/10.1080/21505594.2016.1231295 PMID: 27715466.
15. Varshney AK, Wang X, Aguilar JL, Scharff MD, Fries BC. Isotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice. MBio. 2014; 5(3):e01007–14. https://doi.org/10.1128/mBio.01007-14 PMID: 24917594.
16. Aguilar JL, Varshney AK, Wang X, Stanford L, Scharff M, Fries BC. Detection and measurement of staphylococcal enterotoxin-like K (SEl-K) secretion by Staphylococcus aureus clinical isolates. J Clin Microbiol. 2014; 52(7):2536–43. https://doi.org/10.1128/JCM.00387-14 PMID: 24808237.
17. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet. 2006; 367(9512):731–9. Epub 2006/03/07. https://doi.org/10.1016/S0140-6736(06)68231-7 PMID: 16517273.
18. Li M, Du X, Villaruz AE, Diep BA, Wang D, Song Y, et al. MRSA epidemic linked to a quickly spreading colonization and virulence determinant. Nat Med. 2012; 18(5):816–9. https://doi.org/10.1038/nm.2692PMID: 22522561.
19. Diep BA, Le VT, Badiou C, Le HN, Pinheiro MG, Duong AH, et al. IVIG-mediated protection against nec-rotizing pneumonia caused by MRSA. Sci Transl Med. 2016; 8(357):357ra124. https://doi.org/10.1126/scitranslmed.aag1153 PMID: 27655850.
20. Le VT, Tkaczyk C, Chau S, Rao RL, Dip EC, Pereira-Franchi EP, et al. Critical Role of Alpha-Toxin and Protective Effects of Its Neutralization by a Human Antibody in Acute Bacterial Skin and Skin Structure Infections. Antimicrob Agents Chemother. 2016; 60(10):5640–8. https://doi.org/10.1128/AAC.00710-16PMID: 27401576.
21. Thomsen IP, Sapparapu G, James DB, Cassat JE, Nagarsheth M, Kose N, et al. Monoclonal antibodies against the Staphylococcus aureus bicomponent leukotoxin AB (LukAB) isolated following invasive human infection reveal diverse binding and modes of action. J Infect Dis. 2017. https://doi.org/10.1093/infdis/jix071 PMID: 28186295.
22. Tuchscherr LP, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect Immun. 2008; 76(12):5738–44. Epub 2008/09/24. https://doi.org/10.1128/IAI.00874-08 PMID: 18809660.
23. Hong X, Qin J, Li T, Dai Y, Wang Y, Liu Q, et al. Staphylococcal Protein A Promotes Colonization and Immune Evasion of the Epidemic Healthcare-Associated MRSA ST239. Front Microbiol. 2016; 7:951. https://doi.org/10.3389/fmicb.2016.00951 PMID: 27446000.
24. Nohldén S. Affinity Determination of Protein A Domains to IgG subclasses by Surface Plasmon Resonance [Masters Thesis]2008.
25. Roben PW, Salem AN, Silverman GJ. VH3 family antibodies bind domain D of staphylococcal protein A. J Immunol. 1995; 154(12):6437–45. Epub 1995/06/15. PMID: 7759880.
26. Van Loghem E, Frangione B, Recht B, Franklin EC. Staphylococcal protein A and human IgG subclasses and allotypes. Scand J Immunol. 1982; 15(3):275–8. PMID: 7089488.
27. Peterson PK, Verhoef J, Sabath LD, Quie PG. Effect of protein A on staphylococcal opsonization. Infect Immun. 1977; 15(3):760–4. Epub 1977/03/01. PMID: 870431.
28. Falugi F, Kim HK, Missiakas DM, Schneewind O. Role of protein A in the evasion of host adaptive immune responses by Staphylococcus aureus. MBio. 2013; 4(5):e00575–13. Epub 2013/08/29. https://doi.org/10.1128/mBio.00575-13 PMID: 23982075.
29. Hillson JL, Karr NS, Oppliger IR, Mannik M, Sasso EH. The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A. J Exp Med. 1993; 178(1):331–6. PMID: 8315388.
30. Yang D, Singh A, Wu H, Kroe-Barrett R. Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics. Anal Biochem. 2016; 508:78–96. https://doi.org/10.1016/j.ab.2016.06.024 PMID: 27365220.
31. Moks T, Abrahmsen L, Nilsson B, Hellman U, Sjoquist J, Uhlen M. Staphylococcal protein A consists of five IgG-binding domains. Eur J Biochem. 1986; 156(3):637–43. PMID: 2938951.
32. Jansson B, Uhlen M, Nygren PA. All individual domains of staphylococcal protein A show Fab binding. FEMS Immunol Med Microbiol. 1998; 20(1):69–78. PMID: 9514577.
33. Inganas M, Johansson SG, Bennich HH. Interaction of human polyclonal IgE and IgG from different species with protein A from Staphylococcus aureus: demonstration of protein-A-reactive sites located in the Fab’2 fragment of human IgG. Scand J Immunol. 1980; 12(1):23–31. PMID: 6158089.
34. Inganas M. Comparison of mechanisms of interaction between protein A from Staphylococcus aureus and human monoclonal IgG, IgA and IgM in relation to the classical FC gamma and the alternative F (ab’)2 epsilon protein A interactions. Scand J Immunol. 1981; 13(4):343–52. PMID: 7302528.
35. Nilsson B, Moks T, Jansson B, Abrahmsen L, Elmblad A, Holmgren E, et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. 1987; 1(2):107–13. PMID: 3507693.
36. McGuinness WA, Kobayashi SD, DeLeo FR. Evasion of Neutrophil Killing by Staphylococcus aureus. Pathogens. 2016; 5(1). https://doi.org/10.3390/pathogens5010032 PMID: 26999220.
37. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008; 52(9):3315–20. https://doi.org/10.1128/AAC.00113-08 PMID: 18591266.
38. Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982; 97(3):344–50. PMID: 7114631.
39. Monaco M, Pimentel de Araujo F, Cruciani M, Coccia EM, Pantosti A. Worldwide Epidemiology and Antibiotic Resistance of Staphylococcus aureus. Curr Top Microbiol Immunol. 2016. https://doi.org/10.1007/82_2016_3 PMID: 27025380.
40. Whitehouse J, Flaxman A, Rollier C, O’Shea MK, Fallowfield J, Lindsay M, et al. Population variation in anti-S. aureus IgG isotypes influences surface protein A mediated immune subversion. Vaccine. 2016; 34(15):1792–9. https://doi.org/10.1016/j.vaccine.2016.02.034 PMID: 26921780.
41. Sause WE, Buckley PT, Strohl WR, Lynch AS, Torres VJ. Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections. Trends Pharmacol Sci. 2016; 37(3):231–41. https://doi.org/10.1016/j.tips.2015.11.008 PMID: 26719219.
42. Liese JG, Jendrossek V, Jansson A, Petropoulou T, Kloos S, Gahr M, et al. Chronic granulomatous disease in adults. Lancet. 1996; 347(8996):220–3. Epub 1996/01/27. PMID: 8551880.
43. Cunnion KM, Zhang HM, Frank MM. Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis. Infect Immun. 2003; 71(2):656–62. Epub 2003/01/24. https://doi.org/10.1128/IAI.71.2.656-662.2003 PMID: 12540542.
44. Dryla A, Prustomersky S, Gelbmann D, Hanner M, Bettinger E, Kocsis B, et al. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin Diagn Lab Immunol. 2005; 12(3):387–98. Epub 2005/03/09. https://doi.org/10.1128/CDLI.12.3.387398.2005 PMID: 15753252.
45. Williams RE. Healthy carriage of Staphylococcus aureus: its prevalence and importance. Bacteriol Rev. 1963; 27:56–71. Epub 1963/03/01. PMID: 14000926.
46. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 1997; 10(3):505–20. Epub 1997/07/ 01. PMID: 9227864.
47. Wertheim HF, Vos MC, Ott A, van Belkum A, Voss A, Kluytmans JA, et al. Risk and outcome of nosoco-mial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet. 2004; 364 (9435):703–5. Epub 2004/08/25. https://doi.org/10.1016/S0140-6736(04)16897-9 PMID: 15325835.
48. Herwaldt LA. Staphylococcus aureus nasal carriage: role in continuous ambulatory peritoneal dialysis-associated infections. Perit Dial Int. 1993; 13 Suppl 2:S301–5. Epub 1993/01/01. PMID: 8399593.
49. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005; 5(12):751–62. Epub 2005/ 11/29. https://doi.org/10.1016/S1473-3099(05)70295-4 PMID: 16310147.
50. Darenberg J, Soderquist B, Normark BH, Norrby-Teglund A. Differences in potency of intravenous poly-specific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis. 2004; 38(6):836–42. Epub 2004/03/05. https://doi.org/10.1086/381979 PMID: 14999628.
51. Gauduchon V, Cozon G, Vandenesch F, Genestier AL, Eyssade N, Peyrol S, et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis. 2004; 189(2):346–53. Epub 2004/01/15. https://doi.org/10.1086/380909 PMID: 14722901.
52. Sjoholm I. Protein A from Staphylococcus aureus. Spectropolarimetric and Spectrophotometric studies. Eur J Biochem. 1975; 51(1):55–61. PMID: 235433.
53. O’Halloran DP, Wynne K, Geoghegan JA. Protein A is released into the Staphylococcus aureus culture supernatant with an unprocessed sorting signal. Infect Immun. 2015; 83(4):1598–609. https://doi.org/10.1128/IAI.03122-14 PMID: 25644005.
54. Becker S, Frankel MB, Schneewind O, Missiakas D. Release of protein A from the cell wall of Staphylococcus aureus. Proc Natl Acad Sci U S A. 2014; 111(4):1574–9. Epub 2014/01/18. https://doi.org/10.1073/pnas.1317181111 PMID: 24434550.
55. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med. 2009; 361(2):135–44. https://doi.org/10.1056/ NEJMoa0810603 PMID: 19587338.
56. Gupta SB, Mehta V, Dubberke ER, Zhao X, Dorr MB, Guris D, et al. Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence. Clin Infect Dis. 2016; 63(6):730–4. https://doi.org/10.1093/cid/ciw364 PMID: 27365387.
57. Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. JAMA Pediatr. 2015; 169(4):341–8. https://doi.org/10.1001/jamapediatrics.2014.3804 PMID: 25706618.
58. Sparrow E, Friede M, Sheikh M, Torvaldsen S, Newall AT. Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. Vaccine. 2016; 34 (45):5442–8. https://doi.org/10.1016/j.vaccine.2016.08.057 PMID: 27622299.
59. Nair AB J S. A simple practice guide for dose conversion between animals and human. Journal of Basic and Clinical Pharmacy. 2016; 7(2):27–31. Epub PMID: 27057123.
60. Subrt N, Mesak LR, Davies J. Modulation of virulence gene expression by cell wall active antibiotics in Staphylococcus aureus. J Antimicrob Chemother. 2011; 66(5):979–84. https://doi.org/10.1093/jac/ dkr043 PMID: 21393149.
61. Cazares-Dominguez V, Ochoa SA, Cruz-Cordova A, Rodea GE, Escalona G, Olivares AL, et al. Vancomycin modifies the expression of the agr system in multidrug-resistant Staphylococcus aureus clinical isolates. Front Microbiol. 2015; 6:369. https://doi.org/10.3389/fmicb.2015.00369 PMID: 25999924.